CHIMERIC
THERAPEUTICS

APPENDIX 4C

Quarter Ended 30 September 2025

Chimeric Therapeutics Limited

ACN 638 835 828

ASX: CHM

ASX ANNOUNCEMENT **31 OCTOBER 2025**

QUARTERLY ACTIVITIES REPORT FOR THE PERIOD ENDING 30 SEPTEMBER 2025

Sydney, Australia, 31 October 2025: Chimeric Therapeutics (ASX: CHM, "Chimeric" or the "Company"), a leading Australian cell therapy company, is pleased to provide a summary of its activities for the quarter ended 30 September 2025.

- CHM CDH17 advanced to dose level 2 of 150 million CDH17 CAR-T+ cells
  - CHM CDH17 at a higher dose level continues to demonstrate patient safety
  - Patients treated at Dose Level 2 appears to be well tolerated with a manageable safety profile
  - One patient treated at CHM CDH17 Dose level 1 remains in stable disease more than 10 months after receiving one single dose
- 57% of evaluable high-risk frontline patients in ongoing CHM CORE-NK study have achieved clinical responses, with two new Complete Responses in AML announced
- Internationally recognised haematologist Professor Miles Prince appointed as a Non-Executive Director
- Local manufacturing letter of intent signed with Viral Vector Manufacturing Facility in partnership with New South Wales Government.

Clinical trial updates

CHM CDH17 advances to dose level 2 following encouraging early trial results

In September, the Company reported continued progress from its ongoing CHM CDH17 Phase 1/2 clinical trial, with the Safety Monitoring Committee confirming Dose Level 2 (150 million CHM CDH17 CAR-T+ cells) appears to be well tolerated with a manageable safety profile for further patient enrolment.

To date, four patients have been treated at Dose Level 2. Tumour assessments from two of these patients have shown encouraging evidence of disease control, with reductions in total disease burden of 12% in colorectal cancer and between 6–16% in neuroendocrine tumours. One tumour decreased by 37% in size, consistent with a “mixed response,” meaning some lesions responded while others remained stable. Both patients were classified as having ‘Stable Disease’ under RECIST 1.1 criteria, which defines measurable changes in tumour size used to assess cancer treatments. Importantly, there continues to be no evidence of off-target effects or

gastrointestinal toxicity at this higher dose level, underscoring the therapy's emerging safety profile.

Chimeric also continues to see durable responses in the lower dose cohort. A colorectal cancer patient treated at Dose Level 1 (50 million cells) remains in stable disease more than 10 months after receiving a single dose of CHM CDH17, with one tumour decreasing in size by 18% and showing signs of ongoing improvement.

Lead investigator Professor Jennifer Eads from the University of Pennsylvania said she was "thrilled to see CHM CDH17 demonstrating real anti-tumour activity and durability that can be meaningful for patients".

The Phase 1/2 study (NCT06055439) is designed to determine a recommended Phase 2 dose and evaluate safety and objective response rates in patients with advanced colorectal, gastric, and gastrointestinal neuroendocrine tumours. CHM CDH17 is a first-in-class, third-generation CAR-T cell therapy that targets CDH17—a cancer biomarker associated with poor prognosis and metastasis in gastrointestinal malignancies. Developed at the University of Pennsylvania by Dr Xianxin Hua's laboratory, CHM CDH17 builds on preclinical work published in Nature Cancer in 2022, which showed complete eradication of seven tumour types in animal models.

Chimeric CEO Dr Rebecca McQualter, CMO Dr Jason Litten and Principal Investigator for the trial Professor Jennifer Eads hosted a webinar discussing the CHM CDH17 trial. Click here to view a replay of the event.

CHM CORE-NK Phase 1B Clinical Trial Achieves Additional Complete Responses in AML

Subsequent to the end of the quarter, Chimeric announced additional complete responses from its ongoing ADVENT-AML Phase 1b clinical trial investigating CHM CORE-NK in combination with azacitidine and venetoclax for patients with acute myeloid leukemia (AML). The latest results, presented at the Society of Hematology Oncology Annual Meeting in Houston, revealed that 57% of evaluable high-risk frontline patients in the study have achieved clinical responses, including two new complete responses, adding to the two previously reported.

The combination therapy continues to show a strong safety profile, with no dose-limiting toxicities, cytokine release syndrome, neurotoxicity, or graft-versus-host disease observed.

The dose-escalation phase, completed in late 2024, established the safety of two CORE-NK doses in relapsed or refractory AML patients, with evidence of cell persistence in blood for more than two weeks after repeat infusions and one complete response recorded in that cohort.

Corporate

Professor Miles Prince appointed as Non-Executive Director

Professor H. Miles Prince AM commenced as a Non-Executive Director at the beginning of the quarter.

Professor Prince is an internationally recognised haematologist and Professor of Medicine at both Melbourne and Monash Universities. He holds the position of Professor and Director of Cancer Immunology and Molecular Oncology at Epworth Healthcare and serves as a Haematologist at the Peter MacCallum Cancer Centre. His extensive experience encompasses clinical practice, groundbreaking research in cancer immunology, stem cell therapies, and leadership in clinical trials involving innovative treatments for blood cancers.

Professor Prince has been the Principal Investigator for over 200 clinical trials, notably leading the establishment of the Cell Therapy laboratories at the Peter MacCallum Cancer Centre and pioneering CAR-T therapy trials at both Peter MacCallum and Epworth Healthcare. His contributions to the field are also well recognised with more than 500 peer-reviewed manuscripts.

Partnership with VVMF

Subsequent to the end of the period, the Company announced it had co-signed a Letter of Intent (LOI) with Viral Vector Manufacturing Facility Pty Ltd (VVMF) to enter a strategic supplier relationship focused on the development and GMP-grade manufacturing of Lentiviral vectors (LV).

Under the LOI, VVMF will support process development, technology transfer, and GMP manufacturing of Lentiviral vectors for Chimeric's clinical stage chimeric antigen receptor (CAR-T) program. Viral vectors are a critical component in the production of CAR-T therapies, which are transforming cancer treatment globally.

This partnership marks a significant step forward in strengthening Australia's advanced manufacturing capabilities and the development of Advanced Therapy Medicinal Products (ATMPs). ATMPs are innovative medicines derived from genes, cells, or tissue engineering. They often involve living cells or tissues, requiring highly specialised manufacturing and handling. These therapies offer new treatment possibilities for a range of diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions.

Australia is recognised globally for its support of early-stage biotech companies with a significant R&D tax incentives for eligible activities, a globally recognised and pragmatic regulatory environment, and access to a mature clinical trial ecosystem. This collaboration will enhance

access to cutting-edge therapies for both Australian and international patients with expanded local clinical trial sites.

Financials

An Appendix 4C Quarterly Cash Flow report is attached to this announcement.

As detailed in the attached ASX Appendix 4C the Company had $2.40 million in cash and cash equivalents at 30 September 2025, decreasing from $5.76 million at the end of the prior quarter.

The net cash used in Operating Activities during the quarter was $5.63 million with 90% of operating activities relates to staff costs and research and development as detailed in the Appendix 4C.

The net financing inflows for the quarter was $2.27 million which consists of $4.38 million received as part of the July Placement and Entitlement Offer and outflow of $2.10 million from repayment of the Lind debt facility and transaction costs for the raise.

In accordance with Listing Rule 4.7C, payments made to related parties and their associated included in items 6.1 of the Appendix 4C include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses. The Board has focused on prudent management of cash and as a result careful cost cutting strategy projected total expenditure has and will continue to be reduced.

ABOUT CHIMERIC THERAPEUTICS

Chimeric Therapeutics, a clinical stage cell therapy company is focused on bringing the promise of cell therapy to life for more patients with cancer.

To bring that promise to life for more patients, Chimeric's world class team of cell therapy pioneers is focused on the discovery, development, and commercialization of the most innovative and promising cell therapies.

Chimeric currently has a diversified portfolio that includes first in class autologous CAR T cell therapies and best in class allogeneic NK cell therapies. Chimeric assets are being developed across multiple different disease areas in oncology with 4 clinical stage programs.

CHM CDH17 is a first-in-class, 3rd generation CDH17 CAR T invented at the world-renowned cell therapy centre, the University of Pennsylvania (Penn) in the laboratory of Dr. Xianxin Hua, Professor in the Department of Cancer Biology in the Abramson Family Cancer Research Institute at Penn. Preclinical evidence for CDH17 CAR T was published by Dr. Hua and his colleagues in

2022 in Nature Cancer demonstrating complete eradication of tumours in 7 types of cancer in mice. CHM CDH17 is currently being studied in a phase 1/2 clinical trial in gastrointestinal and neuroendocrine tumours that was initiated in 2024.

CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial was published in March 2022, demonstrating safety and efficacy in blood cancers and solid tumours. Based on the promising activity signal demonstrated in that trial, two additional Phase 1B clinical trials investigating CORE-NK in combination regimens have been initiated.

CHM CLTX is a novel CAR T therapy developed for the treatment of patients with solid tumours. CLTX CAR T is in a phase 1B clinical trial in recurrent / progressive glioblastoma. Positive preliminary data from the investigator-initiated phase 1A trial in glioblastoma was announced in October 2023.

Authorised on behalf of the Chimeric Therapeutics board of directors by Executive Chairman Paul Hopper.

Contact
Investors
Dr Rebecca McQualter
Chief Executive Officer
Chimeric Therapeutics
E: investors@chimerictherapeutics.com
W: www.chimerictherapeutics.com

Media
Matthew Wright
NWR Communications
T: +61 451 896 420
E: matt@nwrcommunications.com.au

-Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Chimeric Therapeutics Limited

ABN	**Quarter ended ("current quarter")**
68 638 835 828	30 September 2025

Consolidated statement of cash flows		**Current quarter $A'000**	**Year to date (3 months) $A'000**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers (inclusive of GST)	-	-
1.2	Payments for (inclusive of GST)		
	(a) research and development	(3,581)	(3,581)
	(b) product manufacturing and operating costs	-	-
	(c) advertising and marketing	-	-
	(d) leased assets	-	-
	(e) staff costs*	(1,516)	(1,516)
	(f) administration and corporate costs	(542)	(542)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	11	11
1.5	Interest and other costs of finance paid	(58)	(58)
1.6	Income taxes paid	-	-
1.7	Government grants and tax incentives	-	-
1.8	Other (provide details if material)	53	53
1.9	**Net cash from / (used in) operating activities**	**(5,633)**	**(5,633)**

*Staff costs includes staff, directors, scientific advisors and employment related costs.

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
2.	**Cash flows from investing activities**		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	**Net cash from / (used in) investing activities**	**-**	**-**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	4,377	4,377
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(439)	(439)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other – repayment of debt facility	(1,665)	(1,665)
3.10	**Net cash from / (used in) financing activities**	**2,273**	**2,273**

Consolidated statement of cash flows		Current quarter $A'000	Year to date (3 months) $A'000
4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of period	5,757	5,757
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(5,633)	(5,633)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	-	-
4.4	Net cash from / (used in) financing activities (item 3.10 above)	2,273	2,273
4.5	Effect of movement in exchange rates on cash held	2	2
4.6	**Cash and cash equivalents at end of period**	**2,399**	**2,399**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter $A'000	Previous quarter $A'000
5.1	Bank balances	2,399	5,757
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**2,399**	**5,757**

6.	**Payments to related parties of the entity and their associates**	Current quarter $A'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	222
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

Item 6.1 – Include payments for remuneration of director fees to executive and non-executive directors in the normal course of business at commercial rates, excluding reimbursements of out-of-pocket expenses.

7.	**Financing facilities** *Note: the term "facility' includes all forms of financing arrangements available to the entity.* *Add notes as necessary for an understanding of the sources of finance available to the entity.*	**Total facility amount at quarter end $A'000**	**Amount drawn at quarter end $A'000**
7.1	Loan facilities	-	-
7.2	Credit standby arrangements	-	-
7.3	Other (please specify)	-	-
7.4	**Total financing facilities**	-	-

7.5	**Unused financing facilities available at quarter end**	-

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

8.	**Estimated cash available for future operating activities**	**$A'000**
8.1	Net cash from / (used in) operating activities (item 1.9)	(5,633)
8.2	Cash and cash equivalents at quarter end (item 4.6)	2,399
8.3	Unused finance facilities available at quarter end (item 7.5)	-
8.4	Total available funding (item 8.2 + item 8.3)	**2,399**
8.5	**Estimated quarters of funding available (item 8.4 divided by item 8.1)**	0.43

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:

8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Answer:

Net cash outflows during the period in operating activities was $5.63 million, with direct research and development expenditure and staff costs accounting for 90% of operating expenditure.

The expenditure was abnormally high this quarter and the Company does not expect to maintain similar levels of spending for the remainder of the financial year.

The Company has focused expenditure on projects that will deliver company milestones. To preserve available resources, operating overheads have been reduced and discretionary expenditure deferred in line with priorities. Going forward the Company is expecting reduced cash burn compared to this quarter. SG&A costs will continue to remain low as the team is not planning personnel expansion over the remainder of the financial year.

8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

Answer:

- The Board is continuing to assess alternative capital sources, and the Directors believe that the Company can raise sufficient capital in the form of equity financing and or non-dilutive inflows. In addition, the Company has and will continue to employ cash management strategies such as delaying discretionary operations activities.

8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Answer:

- Yes, the Board expects to be able to continue its operations and to meet its business objectives based on the responses detailed in 8.6.1 and 8.6.2.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Date: 31 October 2025

Authorised by: The Board
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.

2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.

4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [*name of board committee – eg Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".

5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.

+61 3 9824 5254
info@chimerictherapeutics.com

Chimeric Therapeutics Limited
ACN 638 835 828

ASX: CHM